Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein

Blood

Volumn 88, Issue 8, 1996, Pages 3091-3100

  Carlo Stella, Carmelo ^a   Dotti, Gianpietro ^b   Mangoni, Lina ^b   Regazzi, Ester ^b   Garau, Daniela ^b   Bonati, Antonio ^b   Almici, Camillo ^b   Sammarelli, Gabriella ^b   Savoldo, Barbara ^b   Rizzo, Maria Teresa ^b   Rizzoli, Vittorio ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD34 ANTIGEN; DNA FRAGMENT; DNA NUCLEOTIDYLEXOTRANSFERASE; GENISTEIN; HYDROXYUREA; MAFOSFAMIDE; MESSENGER RNA; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; APOPTOSIS; ARTICLE; BURST FORMING UNIT E; CHRONIC MYELOID LEUKEMIA; COLONY FORMING UNIT; COLONY FORMING UNIT GM; CONTROLLED STUDY; CYTOGENETICS; DIAGNOSIS; DOSE RESPONSE; ENZYME ACTIVITY; FEMALE; GEL ELECTROPHORESIS; GENE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROMYELOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 10244255276     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.8.3091.bloodjournal8883091     Document Type: Article

References (55)

1. Fialkow PJ, Gartler SM, Yoshida A: Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad Sci USA 58:1468, 1967
2. Kurzrock R. Gutterman JU, Talpaz M: The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 319:990, 1988
3. Konopka JB, Watanabe SM, Witte ON: An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37:1035, 1984
4. ber/abl protein. Proc Natl Acad Sci USA 85:9312, 1988
5. ber/abl gene of the Philadelphia chromosome. Science 247:824, 1990
6. McWhirter JR, Wang JYJ: Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr sequences in bcrabl fusion proteins. Mol Cell Biol 11:1553, 1991
7. Shannon K: The Ras signaling pathway and the molecular basis of myeloid leukemogenesis. Curr Opin Hematol 2:305, 1995
8. Mandanas RA, Leibowitz DS, Gharehbaghi K, Tauchi T, Burgess GS, Miyazawa K, Jayaram HN, Boswell HS: Role of p21ras in 210bcr-abl transformation of murine myeloid cells. Blood 82:1838, 1993
9. bcr/abl: Implication for RAS-dependent Philadelphia chromosome positive cell growth. J Exp Med 179:1855, 1994
10. Lowenstein EJ, Daly RJ, Batzer AG, Margolis WL, Lammers R. Ullrich A. Skolnik EY, Bar-Sagi D, Schlessinger J: The SH2 and SH3 domain-containing protein Grb2 links receptor tyrosine kinase to Ras signaling. Cell 70:431, 1992
11. Tauchi T, Boswell HS, Leibowitz D, Broxmeyer HE: Coupling between p210bcr-abl and She and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to Ras activation pathway. J Exp Med 179:167, 1994
12. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, Schlessinger J, Gishizky ML: BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75:175, 1993
13. Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG, Arlinghaus R, Pawson T: Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 13:764, 1994
14. BCR/ABL with paxillin in chronic myelogenous leukemia. J Biol Chem 270:29145, 1995
15. The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon Alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820, 1994
16. Goldman JM: Bone marrow transplantation for chronic myelogenous leukemia. Curr Opin Oncol 4:259, 1992
17. Udomsakdi C, Eaves CJ, Swolin B, Reid DS, Barnett MJ, Eaves AC: Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level. Proc Natl Acad Sci USA 89:6192, 1992
18. McGlave PB, De Fabritiis P, Deisseroth A, Goldman J, Barnett M, Reiffers J, Simonsson B, Carella A, Aeppli D: Autologous transplants for chronic myelogenous leukemia: Results from eight transplants groups. Lancet 343:1486, 1994
19. Daley GD, Goldman JM: Autologous transplant for CML revisited. Exp Hematol 21:734, 1993
20. Reiffers J, Trouette R, Marit G, Montastruc M, Fabères C, Cony-Makhoul P, David B, Bourdeau MJ, Bilhou-Nabera C, Lacombe F, Feuillatre-Fabre F, Vezon G, Bernard Ph, Broustet A: Autologous blood stem cell transplantation for chronic granulocytic leukaemia in transformation: A report of 47 cases. Br J Haematol 77:339, 1991
21. Hoyle C, Gray R, Goldman J: Autografting for patients with CML in chronic phase: An update. Br J Haematol 86:76, 1994
22. McGlave PB, Arthur D, Miller WJ, Lasky L, Kersey J: Autologous transplantation for CML using marrow treated ex vivo with human Interferon gamma. Bone Marrow Transplant 6:115, 1990
23. Carlo-Stella C, Mangoni L, Almici C, Caramatti C, Cottafavi L, Dotti G, Rizzoli V: Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide. Bone Marrow Transplant 14:425, 1994
24. + leukemia cell growth in mice by BCR/ABL antisense oligodeoxynucleotide. Proc Natl Acad Sci USA 91:4504, 1994
25. Carlo-Stella C, Mangoni L, Piovani G, Garau D, Almici C, Rizzoli V: Identification of Philadelphia-negative granulocyte-macrophage colony-forming units generated by stroma-adherent cells from chronic myelogenous leukemia patients. Blood 83:1373, 1994
26. Barnett MJ, Eaves CJ, Phillips GL, Gascoyne R, Hogge DE, Horsman DE, Humphries RK, Klingemann HG, Lansdorp PM, Nantel SH, Reece DE, Shepherd JD, Spinelli JJ, Sutherland HJ, Eaves AC: Autografting with cultured marrow in chronic myeloid leukemia: Results of a pilot study. Blood 84:724, 1994
27. Verfaillie CM, Miller WJ, Boylan K, McGlave PB: Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 79:1003, 1992
28. Leemhuis T, Leibowitz D, Cox G, Silver R, Srour EF, Tricot G, Huffman R: Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow. Blood 81:801, 1993
29. Udomsakdi C, Eaves CJ, Lansdorp PM, Eaves AC: Phenotypic heterogeneity of primitive leukemic hematopoietic cells in patients with chronic myeloid leukemia. Blood 80:2522, 1992
30. Levitzki A, Gazit A: Tyrosine kinase inhibition: An approach to drug development. Science 267:1782, 1995
31. Levitzki A: Tyrphostins - Tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. FASEB J 6:3275, 1992
32. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y: Genistein, a specific inhibitor of tyrosine-specific protein kinase. J Biol Chem 262:5592, 1987
33. Hill TD, Dean NM, Mordan LJ, Lau AF, Kanemitsu MY, Boynton AL: PDGF-induced activation of phospholipase C is not required for induction of DNA sysnthesis. Science 248:1660, 1990
34. Kuriu A, Ikeda H, Kanakura Y, Griffin JD, Drucker B, Yagura H, Kitayama H, Ishikawa J, Nishiura T, Kanayama Y: Proliferation of human myeloid leukemia cell line associated with the tyrosine phosphorylation and activation of the proto-oncogene c-kit product. Blood 78:2834, 1991
35. Traganos F, Ardelt B, Halko N, Bruno S, Darzynkiewicz Z: Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells. Cancer Res 52:6200, 1992
36. Okura A, Arakawa H, Oka H, Yoshinari T, Monden Y: Effect of genistein on topoisomerase activity and on the growth of (Val 12)Ha-ras-transformed NIH cells. Biochem Biophys Res Commun 157:183, 1988
37. Honna Y, Okabe-Kado J, Kasaukabe T, Hozumi M, Umezawa K: Inhibition of abl oncogene tyrosine kinase induces erythroid differentiation of human myelogenous leukemia K-562 cells. Jpn J Cancer Res 81:1132, 1990
38. bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth. Blood 80:1330, 1992
39. bcr/abl tyrosine kinase activity induces K562 to differentiate. Blood 82:3254, 1993
40. Sutherland HJ, Eaves CJ, Eaves AC, Dragowska AC, Lansdorp PM: Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro. Blood 74:1563, 1990
41. Sutherland HJ, Eaves CJ, Lansdorp PM, Tacker JD, Hogge DE: Differential regulation of primitive human hematopoietic cells in long-term cultures maintained on genetically engineered murine stromal cells. Blood 78:666, 1993
42. Yunis JJ: New chromosome techniques in the study of human neoplasia. Hum Pathol 12:540, 1981
43. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate phenol-chloroform extraction. Anal Biochem 162:156, 1987
44. Martial P, Maisin D, Philippe M, Ferrant A, Michaux JL, Cassiman JJ, Van den Berghe H, Sokal G: Detection of residual BCR/ABL transcripts in chronic myeloid leukaemia patients in complete remission using the polymerase chain reaction and nested primers. Br J Haematol 75:355, 1990
45. Melo JV, Kent NS, Van X-H, Goldman JM: Controls for reverse transcriptase-polymerase chain reaction amplification of BCR-ABL transcripts. Blood 84:3984, 1994
46. Smith CA, Williams GT, Kingston R, Jenkinson EJ, Owen JJT: Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures. Nature 337:181, 1989
47. Gorczyca W, Gong J, Darzynkiewicz Z: Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res 53:1945, 1993
48. Rizzo MT, Boswell SH, Mangoni L, Carlo-Stella C, Rizzoli V: Arachidonic acid induces c-jun gene expression in stromal cells stimulated by interleukin-1 and tumor necrosis factor: Evidence for a protein tyrosine kinase dependent process. Blood 86:2967, 1995
49. Anafi M, Gazit A, Gilon C, Ben-Neriah Y, Levitzki A: Selective interactions of transforming and normal abl proteins with ATP, tyrosine-copolymer substrates, and tyrphostins. J Biol Chem 267:4518, 1990
50. Druker BJ, Tamura S, Buchdunger E, Ohno S, Bagby GC, Lydon NB: Preclinical evaluation of a selective inhibitor of the Abl tyrosine kinase as a therapeutic agent for chronic myelogenous leukemia. Blood 86:601a, 1995 (abstr, suppl 1)
51. Hook EB: Exclusion of chromosomal mosaicism: Tables of 90%, 95%, and 99% confidence limits and comments on use. Am J Hum Genet 29:94, 1977
52. Dowding C, Guo A-P, Maisin D, Gordon MY, Goldman JM: The effects of interferon-α on the proliferation of CML progenitor cells in vitro are not related to the precise position of the M-BCR breakpoint. Br J Haematol 77:165, 1991
53. Keating A, Wang X-H, Laraya P: α-Interferon suppresses transcription of BCR-ABL in PH+ chronic myeloid leukemia (CML) progenitor cells. Exp Hematol 21:1073, 1993 (abstr)
54. Kaur G, Gazit A, Levitzki A, Stowe E, Cooney DA, Sausville EA: Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia. Anti-Cancer Drugs 5:213, 1994
55. Gorin NC, Aegerter P, Auvert B, Meloni G, Goldstone AH, Burnett A, Carella A, Korbling M, Herve P, Maraninchi D, Löwenberg B, Verdonck LF, de Planque M, Hermans J, Helbig W, Porcellini A, Rizzoli V, Alessandrino EP, Franklin IM, Reiffers J, Colleselli P, Goldman JM: Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: A European survey of the role of marrow purging. Blood 75:1606, 1990